e-learning
resources
Barcelona 2010
Tuesday, 21.09.2010
Scientific advances in tuberculosis
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Analysis of effect of pentoxyphyllin in fibrosis development in tuberculous patients
B. Prnjavorac, M. Kosnik, A. Jevric-Causevic, J. Mehic, E. Mujaric, A. Mehmedovic-Redzepovic (Sarajevo, Zenica, Bosnia And Herzegovina; Golnil, Slovenia)
Source:
Annual Congress 2010 - Scientific advances in tuberculosis
Session:
Scientific advances in tuberculosis
Session type:
Thematic Poster Session
Number:
5017
Disease area:
Respiratory infections
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
B. Prnjavorac, M. Kosnik, A. Jevric-Causevic, J. Mehic, E. Mujaric, A. Mehmedovic-Redzepovic (Sarajevo, Zenica, Bosnia And Herzegovina; Golnil, Slovenia). Analysis of effect of pentoxyphyllin in fibrosis development in tuberculous patients. Eur Respir J 2010; 36: Suppl. 54, 5017
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Expert interview: TB-Machine learning and artificial intelligence as allies in clinical decision
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Related content which might interest you:
Evaluation of treatment with Nintedanib in patients with idiopathic pulmonary fibrosis: a proteomical approach
Source: International Congress 2019 – Innovations in idiopathic pulmonary fibrosis
Year: 2019
Effects of long-term azithromycin treatment in patients with non-cystic fibrosis stable bronchiectasis
Source: Annual Congress 2007 - Infectious lung and pleural diseases
Year: 2007
Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 50 (4) 1701157; 10.1183/13993003.01157-2017
Year: 2017
Characteristics and management of patients with idiopathic pulmonary fibrosis treated with pirfenidone capsule or tablet formulation
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2016 – IPF treatment II
Year: 2016
Cluster analysis and survival in patients with Idiopathic pulmonary fibrosis
Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries
Year: 2020
Initial clinical experience with nintedanib for treatment of idiopathic pulmonary fibrosis (IPF): About 20 cases
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage
Source: ERJ Open Res, 5 (2) 00127-2018; 10.1183/23120541.00127-2018
Year: 2019
Mechanisms of treatment response to pirfenidone of idiopathic pulmonary fibrosis (IPF) patients
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Effect of metformin on clinically relevant outcomes in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2017 – ILDs: clinical aspects
Year: 2017
Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis
Source: Eur Respir J, 57 (3) 2100283; 10.1183/13993003.00283-2021
Year: 2021
The potential impact of azithromycin in idiopathic pulmonary fibrosis
Source: Eur Respir J, 53 (2) 1800628; 10.1183/13993003.00628-2018
Year: 2019
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Source: Eur Respir J 2015; 45: 1434-1445
Year: 2015
Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function
Source: Eur Respir J 2016; 48: 843-851
Year: 2016
Safety and efficacy of pirfenidone in patients with lung fibrosis and TERT mutation
Source: International Congress 2016 – IPF pathogenesis
Year: 2016
Biomarkers of early relapse of pulmonary exacerbation in cystic fibrosis adult patients
Source: Annual Congress 2013 –Cystic fibrosis: clinical problems and microbiology in adults
Year: 2013
Anti-fibrotic effects of pirfenidone in lung fibroblasts derived from patients with idiopathic pulmonary fibrosis
Source: International Congress 2015 – IPF: from bench to bedside
Year: 2015
Hyaluroman syntehase-2 over expression has impact in the evolution and on the prognosis of idiopathic pulmonary fibrosis patients
Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis
Year: 2012
Benefit of continued pirfenidone treatment following hospitalisation within the first 6 months of therapy—Ad hoc analysis from three phase 3 trials in patients with idiopathic pulmonary fibrosis (IPF)
Source: International Congress 2015 – New frontiers in the management of interstitial and orphan lung diseases
Year: 2015
Effect of baseline statin use on benefit of nintedanib
Source: International Congress 2016 – IPF treatment II
Year: 2016
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept